These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 32441764)

  • 1. Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?
    Curtin N; Bányai K; Thaventhiran J; Le Quesne J; Helyes Z; Bai P
    Br J Pharmacol; 2020 Aug; 177(16):3635-3645. PubMed ID: 32441764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-Ribose) Polymerase Inhibition in Acute Lung Injury. A Reemerging Concept.
    Szabo C; Martins V; Liaudet L
    Am J Respir Cell Mol Biol; 2020 Nov; 63(5):571-590. PubMed ID: 32640172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
    Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
    Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.
    Caracciolo M; Macheda S; Labate D; Tescione M; La Scala S; Vadalà E; Squillaci R; D'Aleo F; Morabito A; Garreffa C; Marciano MC; Oliva EN
    Front Immunol; 2020; 11():1942. PubMed ID: 32983123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19.
    Schumann S; Kaiser A; Nicoletti F; Mangano K; Fagone P; van Wijk E; Yan Y; Schulz P; Ludescher B; Niedermaier M; von Wegerer J; Rauch P; Setz C; Schubert U; Brysch W
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combating devastating COVID-19 by drug repurposing.
    Pawar AY
    Int J Antimicrob Agents; 2020 Aug; 56(2):105984. PubMed ID: 32305589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies.
    Sharma A; Tiwari S; Deb MK; Marty JL
    Int J Antimicrob Agents; 2020 Aug; 56(2):106054. PubMed ID: 32534188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.
    Orienti I; Gentilomi GA; Farruggia G
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
    Badawy AA
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33063092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
    Yao Z; Zheng Z; Wu K; Junhua Z
    Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characteristics of SARS-CoV-2 and potential pharmacological treatment].
    Pawlik L; Śpiołek E; Fichna J; Tarasiuk A
    Postepy Biochem; 2020 May; 66(2):83-90. PubMed ID: 32700510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tackling the cytokine storm in COVID-19, challenges and hopes.
    Abdin SM; Elgendy SM; Alyammahi SK; Alhamad DW; Omar HA
    Life Sci; 2020 Sep; 257():118054. PubMed ID: 32663575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
    Yaqinuddin A; Kashir J
    Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.